PDCD1 and neoplasm: It was demonstrated that evaluation of early tumor response by RECIST 1.1 and mRECIST failed to correlate with the OS of patients with uHCC treated with an anti-PD-1 antibody plus bevacizumab, while the evaluation using the Choi and rChoi criteria significantly correlated with OS.